Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: Stanford Medical School
Location: 401 Quarry Rd, Palo Alto, CA 94304
Lead Doctor: Dr. Greg Sahlem
IRB Committee: This study has been reviewed and approved by the Institutional Review Board

Cannabis use disorder (CUD) is a common problem in the United States, and more Americans than ever have been diagnosed with it. CUD can have a large and negative impact on health and quality of life. Due to the increase in incidence of CUD and the negative health and quality of life effects, there has been an increase in the number of folks with CUD who are seeking treatment and studies have shown that cannabis reduction or cessation can reverse these negative health and quality of life effects..

Currently, there is no approved medication for those with CUD and healthcare professionals have few options to offer those with CUD who are trying to reduce the amount of cannabis they use. . This study is investigating the effectiveness of a treatment called Transcranial Magnetic Stimulation (rTMS) that is currently FDA approved and is commonly used to treat depression, OCD, and smoking cessation if medications are not helpful. Researchers are interested in understanding if by treating people who have CUD with rTMS can reduce cannabis (marijuana) use and craving and impact how the brain responds to cannabis-related images.

This study seeks adults aged 18 to 65 years old who use marijuana on a daily basis, and are interested in reducing the amount of marijuana they use or stop marijuana altogether.Participants must attend 24 study site visits over approximately 4 months.

• You may receive a new potential CUD treatment.
• You will receive marijuana counseling at no cost.
• You may experience a decrease in cannabis use and craving.
• You will be helping to advance medical research.

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
• Qualified health professionals will monitor your health as it relates to the study.

• Adults aged 18 to 65 years old who use cannabis on a daily basis.
• Must have the desire to use less cannabis or quit completely.
• Able to attend 24 study visits at the research site over approximately 4 months.
  Please note that each study visit may take between 1.5-3 hours.

The use of rTMS is not FDA approved for the use of cannabis use disorder and is investigational in this study.
Participant’s rights questions, contact 1-866-680-2906.